These companies are developing stem cell-derived beta cells to replace those destroyed in the autoimmune attack.
This record-high funding will ensure the SDP continues to provide critical support for the treatment, prevention, and cure of T1D.
The T1D Fund can push cell supply solutions across the finish line in the near term, but it will require a paradigm shift.
UP421 is the first clinical trial to protect insulin-producing cells without immunosuppression in a T1D patient, but how does it fare long term?
Recommendations and actions for Breakthrough T1D to consider in 2026 to make it a truly ‘breakthrough’ year.
The most impactful T1D Practical Cure highlights of 2025.
